期刊
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
卷 19, 期 11, 页码 1312-1317出版社
WILEY
DOI: 10.1111/j.1440-1746.2004.03459.x
关键词
adverse reaction; anemia; discontinuation; hemoglobin; interferon; ribavirin
Background and Aim: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia. This study was conducted to identify the factors contributing to ribavirin-induced anemia. Methods: Eighty-eight patients with chronic hepatitis C who received interferon-alpha-2b at a dose of 6 MU administered intramuscularly for 24 weeks in combination with ribavirin administered orally at a dose of 600 mg or 800 mg participated in the study. A hemoglobin concentration of <10 g/dL was defined as ribavirin-induced anemia. Results: Ribavirin-induced anemia occurred in 18 (20.5%) patients during treatment. A 2 g/dL decrease in hemoglobin concentrations in patients with anemia was observed at week 2 after the start of treatment. The hemoglobin concentration in patients with >= 2 g/dL decrease at week 2 was observed to be significantly lower even after week 2 than in patients with <2 g/dL decrease (P < 0.01). A significant relationship was observed between the rate of reduction of hemoglobin concentrations at week 2 and the severity of anemia (P < 0.01). Such factors as sex (female), age (greater than or equal to60 years old), and the ribavirin dose by body weight (12 mg/kg or more) were significant by univariate analysis. Conclusions: Careful administration is necessary in patients greater than or equal to60 years old, in female patients, and in patients receiving a ribavirin dose of 12 mg/kg or more. Patients who experience a fall in hemoglobin concentrations of 2 g/dL or more at week 2 after the start of treatment should be monitored with particular care. (C) 2004 Blackwell Publishing Asia Pry Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据